Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lafutidine + irsogladine maleate
- Development stage
- Phase 1
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is an **oral fixed-dose combination tablet** containing **lafutidine**, a histamine H2 receptor antagonist, and **irsogladine maleate**, a gastroprotective agent. Lafutidine reduces gastric acid secretion by competitively inhibiting histamine H2 receptors on gastric parietal cells. Irsogladine maleate enhances gastric mucosal protection via multiple mechanisms, including activation of cyclic AMP, promotion of nitric oxide synthesis, opening of ATP-sensitive potassium channels, increasing endogenous prostaglandins, activating TRPV1 channels, and possessing antioxidant properties. The combination is investigated for **gastrointestinal mucosal protection and ulcer prevention or healing**, especially in conditions associated with nonsteroidal anti-inflammatory drug (NSAID) use, gastritis, or peptic ulcers.
- Brand names
- none known as a fixed dose combination
- Other names
- lafutidine and irsogladine maleate combination
02
Targets
PDE (Phosphodiesterase family)HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on lafutidine + irsogladine maleate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lafutidine + irsogladine maleate.